|Year : 2017 | Volume
| Issue : 4 | Page : 921-922
Author's Reply: Choice of antiepileptic drugs in the treatment of tumor-related epilepsy
Sandeep Mittal1, Aashit K Shah2
1 Department of Neurosurgery, Oncology, Wayne State University School of Medicine, Comprehensive Epilepsy Center, Detroit Medical Center and Wayne State University, Multidisciplinary Neuro-Oncology Program, Karmanos Cancer Institute, Detroit, Michigan, USA
2 Department of Neurology, Wayne State University School of Medicine, Comprehensive Epilepsy Center, Detroit Medical Center and Wayne State University, Detroit, Michigan, USA
|Date of Web Publication||5-Jul-2017|
Department of Neurosurgery, Wayne State University, 4160 John R Street, Suite 930, Detroit, Michigan - 48201
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Mittal S, Shah AK. Author's Reply: Choice of antiepileptic drugs in the treatment of tumor-related epilepsy. Neurol India 2017;65:921-2
We truly appreciate and welcome the question raised regarding the choice of antiepileptic drugs (AEDs) in the treatment of tumor-related epilepsy (TRE). As you have pointed out, there is no strong evidence supported by prospective randomized clinical trials to indicate that the choice of one AED is superior in patients with TRE. In the absence of well-controlled randomized trials, the decision on choice of AED that provides the best risk–benefit ratio is somewhat arbitrary and based mainly on the treating physician's preference and experience.
As we have mentioned in our article, several studies have shown that the pharmacokinetic and pharmacodynamics interactions between the AEDs and medications commonly used in patients with brain tumors render enzyme-inducing AEDs less desirable as they may reduce the efficacy of many chemotherapeutic agents. The newer AEDs are generally associated with fewer side effects and are typically better tolerated in patients with TRE, who often have impaired neurological function at baseline. Due to these reasons, newer AEDs are preferred for treatment in patients with TRE in North America and Europe.
| » References|| |
Klinger NV, Shah AK, Mittal S. Management of brain tumor-related epilepsy. Neurol India 2017;65:60-70.
] [Full text]
Rogers LR. Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know. Epilepsia 2013;4(Suppl 9):105-8.
Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 2013;54(Suppl 9):97-104.